Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

This study has been terminated.
(Decision was made not to attempt a lower dose)
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: January 2, 2007
Last updated: December 19, 2007
Last verified: October 2007
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2007
  Estimated Primary Completion Date: No date given